Safety and Efficacy of Satralizumab in Patients with Relapsing MOGAD
Dr. Shuvro Roy and Dr. Michael Levy discuss satralizumab for treating relapsing MOGAD, current management challenges, and the encouraging results of this new therapy. Read more about this abstract .
Read the full articleYou might also wanna read
Indiana teen with rare autoimmune disorder MOGAD finds specialized care at Mayo Clinic after years of relapses
For years, Brody Kalk and his family lived with a diagnosis. What they needed was confidence in what came next. Despite treatment close to h
mayocl.in·9d ago
EFL070 – Dosing Strategies for Remission in Graves Disease
For our 70th episode, we review a paper that tries to improve our understanding of remission in Graves’ disease. Long-term thionamide treatm
Q&A 168 - Is it a relapse on ofatumumab?
The question of whether this is a new relapse or the emergence of smouldering MS in a pathway with reduced reserve is difficult without exam
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
Savolitinib shows promise for MET^amp^ gastric/GEJ cancer: Phase 2 data reveal potential as a targeted therapy in this poor prognosis group.
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Conditions : Relapsed or Refractory Multiple Myeloma Interventions : Biological: AZD4045; Drug: Daratumumab; Drug: Aldesleukin Sponsors : As
Comments
Sign in to join the conversation.
No comments yet. Be the first.